Altamira Therapeutics Ltd. (CYTO)
NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 3.25M |
| Enterprise value | 2.68M |
| Trailing P/E | 3.38 |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 0.64 |
| Price/book (mrq) | 0.46 |
| Enterprise value/revenue | 64.93 |
| Enterprise value/EBITDA | -0.47 |
Trading information
Stock price history
| Beta (5Y monthly) | 2.55 |
| 52-week change 3 | -92.25% |
| S&P500 52-week change 3 | 26.27% |
| 52-week high 3 | 23.6000 |
| 52-week low 3 | 1.3500 |
| 50-day moving average 3 | 1.7951 |
| 200-day moving average 3 | 3.8086 |
Share statistics
| Avg vol (3-month) 3 | 1.19M |
| Avg vol (10-day) 3 | 54.37k |
| Shares outstanding 5 | 2.24M |
| Implied shares outstanding 6 | 2.32M |
| Float 8 | 2.22M |
| % held by insiders 1 | 0.89% |
| % held by institutions 1 | 0.34% |
| Shares short (30 Apr 2024) 4 | 145.17k |
| Short ratio (30 Apr 2024) 4 | 0.59 |
| Short % of float (30 Apr 2024) 4 | 6.54% |
| Short % of shares outstanding (30 Apr 2024) 4 | 6.48% |
| Shares short (prior month 28 Mar 2024) 4 | 444.46k |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | 01 May 2019 |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | 1:20 |
| Last split date 3 | 13 Dec 2023 |
Financial highlights
Currency in CHF.Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Dec 2023 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | 0.00% |
Management effectiveness
| Return on assets (ttm) | -52.83% |
| Return on equity (ttm) | N/A |
Income statement
| Revenue (ttm) | N/A |
| Revenue per share (ttm) | N/A |
| Quarterly revenue growth (yoy) | N/A |
| Gross profit (ttm) | N/A |
| EBITDA | -5.8M |
| Net income avi to common (ttm) | -7.27M |
| Diluted EPS (ttm) | -16.3000 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 617.41k |
| Total cash per share (mrq) | 0.28 |
| Total debt (mrq) | 99.66k |
| Total debt/equity (mrq) | 1.54% |
| Current ratio (mrq) | 1.38 |
| Book value per share (mrq) | 4.37 |
Cash flow statement
| Operating cash flow (ttm) | -11.51M |
| Levered free cash flow (ttm) | -9.18M |
© 2024 Yahoo. All rights reserved.